Updates are available Correction dated 2019-09-07
Click to view Correction: https://doi.org/10.1007/s00259-019-04514-1
-
Authors
Michaud, Laure http://orcid.org/0000-0002-0234-2309
Beattie, B. J.
Akhurst, T.
Dunphy, M.
Zanzonico, P.
Finn, R.
Mauguen, A.
Schöder, H.
Weber, W. A.
Lassman, A. B.
Blasberg, R.
- License Information
-
More Information
Article History
Received: 25 March 2019
Accepted: 9 July 2019
First Online: 15 August 2019
Change Date: 7 September 2019
Change Type: Correction
Change Details: The article <Superscript>18</Superscript>F-Fluciclovine (<Superscript>18</Superscript>F-FACBC) PET imaging of recurrent brain tumors written by Laure Michaud, B. J. Beattie, T. Akhurst, M. Dunphy, P. Zanzonico, R. Finn, A. Mauguen, H. Schöder, W. A. Weber, A. B. Lassman, R. Blasberg.
Compliance with ethical standards
:
: Blue Earth Diagnostics provided support for the data analysis and paid for a part of Dr. L. Michaud salary.This research was funded in part by Dr. A.B. Lassman’s grants from Dana Foundation, Brain Tumor Funders’ Collaborative, The Society of Memorial Sloan-Kettering Cancer Center, Brain Tumor Center of Memorial Sloan Kettering Cancer Center, Mr. William H. Goodwin and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer Research and The Experimental Therapeutics Center of Memorial Sloan Kettering Cancer Center. In the last 12 months, outside the submitted work, Dr. A.B. Lassman received: Personal fees/honoraria from Orbus, Karyopharm, NW Bio, AbbVie, Agios, Bioclinica as an expert blinded independent reviewer of clinical and imaging data for a BMS-sponsored trial, Sapience, Physicians’ Education Resource/Chemotherapy Foundation Symposium; Research support from Genentech/Roche, Amgen, AbbVie, Millenium, Celldex, Novartis, Pfizer, Aeterna Zenaris, Karyopharm, RTOG-Foundation, Kadmon, VBI Vaccines, Beigene, Oncoceutics; and Travel/in-kind support from Orbus, Karyopharm, NW Bio, Oncoceutics, GCAR, Agios, AbbVie, Celgene, Novocure, Tocagen.Dr. H. Schoder has no actual conflict of interest. He was a consultant for Aileron Pharmaceuticals until June 30, 2018.Dr. WA. Weber is on advisory boards and receives compensation from Bayer, Blue Earth Diagnostics, Endocyte and Pentixapharm. He has received research support from BMS, Imaginab, Ipsen and Piramal.B.J. Beattie, Dr. T. Akhurst, P. Zanzonico, Dr. M. Dunphy, Dr. R. Finn, A. Mauguen, and Dr. R. Blasberg declare they have no conflict of interest.
: All procedures performed in this study were in accordance with the ethical standards of our institution and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
